Recombinant Human Anti-VEGFR2 x Human Anti-VEGFR3 Bispecific Antibody (scIgG) (SCIGG-H353)

Recombinant Anti-VEGFR2 x Anti-VEGFR3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-VEGFR2 and anti-VEGFR3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can block two receptors simultaneously. It is designed for the research of Cancers therapy.

Datasheet INQUIRY

Specifications

Targets

VEGFR2 & VEGFR3

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Cancers

Targets

Target 1

VEGFR2

Gene ID

3791

UniProt ID

A0A024RD88

Alternative Names

FLK1; CD309; VEGFR; VEGFR2; Vascular endothelial growth factor receptor 2; Kinase insert domain receptor; Fetal liver kinase 1; Kinase insert domain receptor, a type III receptor; KDR

Target 2

VEGFR3

Gene ID

2324

UniProt ID

P35916

Alternative Names

FLT4; PCL; FLT-4; FLT41; LMPH1A; VEGFR3; VEGFR-3; fms related tyrosine kinase 4; Vascular endothelial growth factor 3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-VEGFR2 x Human Anti-VEGFR3 Bispecific Antibody (scIgG) (SCIGG-H353). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-VEGFR2 x Human Anti-VEGFR3 Bispecific Antibody (scIgG) (CAT#: SCIGG-H353)

Specifications

Targets

Customer Reviews and Q&As